The common and persistent failures to translate promising preclinical drug candidates into
clinical success highlight the limited effectiveness of disease models currently used in drug …

The early and efficient assessment of cardiac safety liabilities is essential to confidently
advance novel drug candidates. This article discusses evolving mechanistically based …

Cardiomyocytes from human pluripotent stem cells (hPSCs-CMs) could revolutionise
biomedicine. Global burden of heart failure will soon reach USD $90 bn, while unexpected …

Cardiovascular diseases (CVDs) are pointed out by the World Health Organization (WHO)
as the leading cause of death, contributing to a significant and growing global health and …

High-content screening (HCS) technology combining automated microscopy and
quantitative image analysis can address biological questions in academia and the …

An in vitro drug-induced cardiotoxicity assay is a critical step in drug discovery for clinical
use. The use of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) …

Human induced pluripotent stem cells (hiPSCs) have revolutionized the field of human
disease modeling, with an enormous potential to serve as paradigm shifting platforms for …

The sarcomere is the contractile unit within cardiomyocytes driving heart muscle contraction.
We sought to test the mechanisms regulating actin and myosin filament assembly during …

A major hurdle for cardiovascular disease researchers has been the lack of robust and
physiologically relevant cell-based assays for drug discovery. Derivation of cardiomyocytes …

Induced pluripotent stem cell (iPSC) technology is creating exciting new opportunities for
cardiovascular research by providing platforms to study the mechanisms of disease …